Shine Investment Advisory Services Inc buys $736,220 stake in STAAR Surgical Company (STAA)

STAAR Surgical Company (STAA) : Shine Investment Advisory Services Inc scooped up 22,400 additional shares in STAAR Surgical Company during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 19, 2016. The investment management firm now holds a total of 112,400 shares of STAAR Surgical Company which is valued at $736,220.STAAR Surgical Company makes up approximately 0.82% of Shine Investment Advisory Services Inc’s portfolio.

Other Hedge Funds, Including , Simplex Trading reduced its stake in STAA by selling 3,855 shares or 97.67% in the most recent quarter. The Hedge Fund company now holds 92 shares of STAA which is valued at $603.Creative Planning reduced its stake in STAA by selling 14,700 shares or 29.06% in the most recent quarter. The Hedge Fund company now holds 35,890 shares of STAA which is valued at $223,236.Cutler Group Lp reduced its stake in STAA by selling 848 shares or 73.87% in the most recent quarter. The Hedge Fund company now holds 300 shares of STAA which is valued at $1,866. Bnp Paribas Arbitrage Sa added STAA to its portfolio by purchasing 1,547 company shares during the most recent quarter which is valued at $9,267.

STAAR Surgical Company opened for trading at $6.47 and hit $6.7 on the upside on Wednesday, eventually ending the session at $6.55, with a gain of 1.39% or 0.09 points. The heightened volatility saw the trading volume jump to 36,727 shares. Company has a market cap of $263 M.

On the company’s financial health, STAAR Surgical Company reported $-0.01 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on May 11, 2016. Analyst had a consensus of $0.02. The company had revenue of $19.30 million for the quarter, compared to analysts expectations of $19.60 million. The company’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.03 EPS.

Many Wall Street Analysts have commented on STAAR Surgical Company. The Benchmark Company Upgraded STAAR Surgical Company on May 18, 2016 to ” Buy”, Price Target of the shares are set at $6.

STAAR Surgical Company designs develops manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The Company’s principal products are intraocular lenses (IOLs) and implantable Collamer lenses (ICLs). IOLs are prosthetic intraocular lenses used to restore vision that has been adversely affected by cataracts and include the Company’s lines of silicone and Collamer IOLs and the Preloaded Injector (a silicone or acrylic IOL preloaded into a single-use disposable injector). ICLs consisting of the Company’s ICL and Toric implantable collamer lenses (TICL) are intraocular lenses used to correct refractive conditions such as myopia (near-sightedness) hyperopia (far-sightedness) and astigmatism. The Company operates under the brands STAAR Visian Collamer CentraFLOW AquaPORT nanoFLEX nanoPOINT Epiphany and AquaFlow. Collamer is the brand name for its collagen copolymer lens material.

Leave a Reply

STAAR Surgical Company - Is it time to Sell?

Top Brokerage Firms are advising their investors on STAAR Surgical Company. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.